|
시장보고서
상품코드
2149285
바이오 분석 시험 서비스 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)Bioanalytical Testing Services Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
바이오 분석 시험 서비스 시장 성장요인
세계 바이오 분석 시험 서비스 시장 규모는 2025년에 57억 2,000만 달러로 평가되며, 2026년 62억 6,000만 달러에서 2034년까지 123억 달러로 성장하여, 2026년부터 2034년까지 연평균 성장률(CAGR) 8.8%를 기록할 것으로 예측됩니다. 북미는 광범위한 제약 연구, 생명공학 개발, 임상시험 및 첨단 분석 시험 서비스에 대한 수요에 힘입어 2025년 43.53%의 점유율을 차지하며 시장을 주도했습니다.
바이오 분석 시험 서비스에는 생체 시료 내 의약품, 대사산물, 바이오마커 및 기타 물질의 동정 및 정량이 포함됩니다. 바이오의약품 및 첨단 치료법 개발의 진전, 제약·생명공학 분야의 연구개발비 증가, 아웃소싱 활동의 확대, 그리고 정밀의학(Precision Medicine)의 적용 범위 확대가 시장 성장을 뒷받침하고 있습니다. 제약 회사와 생명공학 기업들은 약동학, 독성동태학, 면역원성, 바이오마커, 대사산물 및 약물 농도 분석에 있어 전문 검사 기관이나 CRO(의약품 개발 수탁 기관)에 대한 의존도를 높이고 있습니다.
바이오분석 시험 서비스 시장의 동향
실험실 워크플로우의 디지털화 및 자동화 : 실험실에서는 로봇식 액체 핸들러, 자동 시료 전처리 시스템, 실험실 정보 관리 시스템 및 클라우드 연결형 분석 플랫폼의 도입이 점점 더 확대되고 있습니다. 이러한 기술을 통해 시료 추적, 데이터 전송, 분석의 일관성, 워크플로우 효율성 및 데이터 추적성이 향상됩니다. 전임상 및 임상 프로그램에서 생물학적 시료의 양이 점점 증가하고 있기 때문에 자동화는 특히 중요한 가치를 지니고 있습니다.
시장 역학
시장 촉진요인 : 제약 및 생명공학 분야의 연구개발 파이프라인 확대는 여전히 주요 성장 요인으로 작용하고 있습니다. 신약 후보 물질에 대해서는 신약 개발, 전임상 개발, 임상시험의 모든 단계에 걸쳐 생물학적 분석 검사가 필요합니다. 검사 업무의 아웃소싱 증가, 바이오의약품 개발 확대, 엄격한 규제 요건, 그리고 바이오마커 및 정밀 의학의 채택 확대가 수요를 더욱 부추기고 있습니다.
시장 제약요인 : 첨단 바이오분석 기술에 수반되는 높은 비용은, 특히 중소규모 연구소에서 도입을 저해할 가능성이 있습니다. 고분해능 질량 분석기, LC-MS/MS 시스템, 유세포 분석기, 멀티플렉스 면역측정 플랫폼, 자동 액체 처리 시스템 및 관련 인프라에는 막대한 설비 투자가 필요합니다. 숙련된 바이오분석 연구자의 부족과 분석법 개발 및 규제 준수의 복잡성도 제약요인으로 작용하고 있습니다.
시장 기회 : 신흥국의 의료 인프라 및 임상 연구 활동 확대는 서비스 제공업체에게 기회를 창출하고 있습니다. 인도나 브라질 등의 국가에서 병원, 연구 센터, 바이오뱅크, CRO, CDMO의 수가 증가하고 있으며, 이는 수요를 뒷받침할 것으로 예상됩니다.
시장의 과제 : 일부 신흥 경제국에서 연구 집약형 제약사나 생명공학 기업의 진출이 제한적이라는 점은 여전히 과제로 남아 있습니다. 일부 국가에서는 제약 활동이 제네릭 의약품, 제제, 포장, 위탁 제조에 집중되어 있는 반면, 임상 연구나 혁신적인 의약품 개발은 비교적 제한적인 수준에 머물러 있습니다.
세분화 분석
분석 시험 유형별 : 2025년에는 의약품 개발 활동의 활성화에 힘입어 약동학/독성동태학 및 약물 농도 분석이 1위를 차지했습니다. 면역원성 시험은 예측 기간 동안 연평균 성장률(CAGR) 9.3%로 성장할 것으로 전망됩니다.
분자 유형별 : 2025년에는 단일클론 항체, 바이오시밀러 및 기타 생물학적 제제의 개발 확대를 배경으로, 고분자 화합물 및 기존 생물학적 제제가 39.9%의 점유율을 차지하며 시장을 주도했습니다. 첨단 치료법은 연평균 성장률(CAGR) 9.2%로 성장할 것으로 예측됩니다.
기술별 : 2025년에는 높은 처리량과 분석 능력을 바탕으로 직접 크로마토그래피·질량 분석법이 37.8%의 점유율을 차지했습니다. 유세포 분석법은 연평균 성장률(CAGR) 10.6%를 기록할 것으로 예측됩니다.
최종사용자별 : 2025년에는 제약사 및 생명공학 기업이 시장을 독점하고 있으며, 2026년에는 69.5%를 차지할 것으로 예상됩니다. CRO 및 CDMO는 연평균 성장률(CAGR) 9.9%로 확대될 것으로 예측됩니다.
바이오 분석 시험 서비스 시장의 지역별 전망
북미 : 북미는 계속해서 최대 지역으로, 2025년에는 24억 9,000만 달러에 달했습니다. 미국은 2026년에 약 25억 3,000만 달러로 추정되며, 전 세계 매출의 약 40.4%를 차지할 전망입니다.
유럽 : 유럽은 제약 분야의 연구개발 및 LC-MS/MS를 활용한 시험 도입 확대에 힘입어 2026년에는 17억 3,000만 달러에 달할 것으로 예측됩니다. 2026년 영국의 시장 규모는 약 3억 7,000만 달러, 독일은 3억 3,000만 달러로 예측됩니다.
아시아태평양 : 아시아태평양은 검사실 처리 능력 확대와 의료비 증가에 힘입어 2026년에는 12억 7,000만 달러에 달할 것으로 추산됩니다. 2026년 일본 시장은 2억 9,000만 달러, 중국 시장은 4억 1,000만 달러, 인도 시장은 1억 8,000만 달러로 추산됩니다.
라틴아메리카 및 중동 및 아프리카 : 라틴아메리카는 2026년에 3억 2,000만 달러에 달할 것으로 예측되며, GCC 시장은 1억 5,000만 달러에 달할 것으로 전망됩니다. 남아프리카는 2026년에 약 5,000만 달러에 달할 것으로 추산됩니다.
보고서의 범위
본 보고서는 전 세계 바이오 분석 시험 서비스 시장에 대해 시장 규모 및 전망, 주요 성장 요인, 제약요인, 기회, 과제, 트렌드, 분석 테스트 유형, 분자, 기술, 최종사용자별 세분화, 지역별 분석, 경쟁 구도, 주요 기업 및 최근 업계 동향을 포함한 상세한 분석을 제공합니다. 시장 규모는 2025년에 57억 2,000만 달러로 평가되며, 2026년에는 62억 6,000만 달러에 달할 것으로 예측되고, 2034년까지 123억 달러에 달할 것으로 전망됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 역학
제4장 주요 인사이트
제5장 세계의 바이오 분석 시험 서비스 시장 분석, 인사이트, 예측, 2021-2034년
제6장 북미의 바이오 분석 시험 서비스 시장 분석, 인사이트, 예측, 2021-2034년
제7장 유럽의 바이오 분석 시험 서비스 시장 분석, 인사이트, 예측, 2021-2034년
제8장 아시아태평양의 바이오 분석 시험 서비스 시장 분석, 인사이트, 예측, 2021-2034년
제9장 라틴아메리카의 바이오 분석 시험 서비스 시장 분석, 인사이트, 예측, 2021-2034년
제10장 중동 및 아프리카의 바이오 분석 시험 서비스 시장 분석, 인사이트, 예측, 2021-2034년
제11장 경쟁 분석
KSM 26.10.22Growth Factors of bioanalytical testing services Market
The global bioanalytical testing services market size was valued at USD 5.72 billion in 2025 and is projected to grow from USD 6.26 billion in 2026 to USD 12.30 billion by 2034, exhibiting a CAGR of 8.8% from 2026 to 2034. North America dominated the market with a 43.53% share in 2025, supported by extensive pharmaceutical research, biotechnology development, clinical trials, and demand for advanced analytical testing services.
Bioanalytical testing services involve identifying and quantifying drugs, metabolites, biomarkers, and other substances in biological samples. Growing development of biologics and advanced therapeutic modalities, increasing pharmaceutical and biotechnology R&D expenditure, rising outsourcing activities, and expanding precision medicine applications are supporting market growth. Pharmaceutical and biotechnology companies increasingly rely on specialized laboratories and CROs for pharmacokinetic, toxicokinetic, immunogenicity, biomarker, metabolite, and drug concentration analysis.
BIOANALYTICAL TESTING SERVICES MARKET TRENDS
Digitalization and Automation of Laboratory Workflows: Laboratories are increasingly adopting robotic liquid handlers, automated sample-preparation systems, laboratory information management systems, and cloud-connected analytical platforms. These technologies improve sample tracking, data transfer, assay consistency, workflow efficiency, and data traceability. Automation is particularly valuable as preclinical and clinical programs generate increasing volumes of biological samples.
MARKET DYNAMICS
Market Drivers: Expansion of pharmaceutical and biotechnology R&D pipelines remains a major growth factor. New drug candidates require bioanalytical testing throughout discovery, preclinical development, and clinical trials. Increasing outsourcing of testing activities, growing development of biologics, stringent regulatory requirements, and rising adoption of biomarkers and precision medicine are further supporting demand.
Market Restraints: High costs associated with advanced bioanalytical technologies can restrict adoption, particularly among small and mid-sized laboratories. High-resolution mass spectrometers, LC-MS/MS systems, flow cytometers, multiplex immunoassay platforms, automated liquid-handling systems, and related infrastructure require significant capital investment. A shortage of skilled bioanalytical scientists and complexity in assay development and regulatory compliance also create constraints.
Market Opportunities: Expansion of healthcare infrastructure and clinical research activities across emerging countries creates opportunities for service providers. Increasing numbers of hospitals, research centers, biobanks, CROs, and CDMOs in countries such as India and Brazil are expected to support demand.
Market Challenges: The limited presence of research-intensive pharmaceutical and biotechnology companies in several emerging economies remains a challenge. In some countries, pharmaceutical activity is concentrated on generics, formulations, packaging, and contract manufacturing, while clinical research and innovative drug development remain comparatively limited.
SEGMENTATION ANALYSIS
By Analytical Testing Type: Pharmacokinetic/toxicokinetic and drug concentration analysis held the leading position in 2025, supported by increasing drug-development activity. Immunogenicity testing is projected to grow at a 9.3% CAGR during the forecast period.
By Molecule: Large molecules and conventional biologics dominated with a 39.9% share in 2025, driven by growing development of monoclonal antibodies, biosimilars, and other biologics. Advanced therapeutic modalities are projected to grow at a 9.2% CAGR.
By Technology: Direct chromatography-mass spectrometry accounted for a 37.8% share in 2025, supported by high throughput and analytical capabilities. Flow cytometry is projected to record a 10.6% CAGR.
By End User: Pharmaceutical and biotechnology companies dominated the market in 2025 and are expected to account for 69.5% in 2026. CROs and CDMOs are projected to expand at a 9.9% CAGR.
BIOANALYTICAL TESTING SERVICES MARKET REGIONAL OUTLOOK
North America: North America remained the leading region, reaching USD 2.49 billion in 2025. The U.S. is estimated at approximately USD 2.53 billion in 2026, representing around 40.4% of global sales.
Europe: Europe is projected to reach USD 1.73 billion in 2026, supported by pharmaceutical R&D and increasing adoption of LC-MS/MS-based testing. The U.K. is estimated at approximately USD 0.37 billion, while Germany is projected at USD 0.33 billion in 2026.
Asia Pacific: Asia Pacific is estimated at USD 1.27 billion in 2026, supported by expanding laboratory capacity and healthcare expenditure. Japan is estimated at USD 0.29 billion, China at USD 0.41 billion, and India at USD 0.18 billion in 2026.
Latin America and Middle East & Africa: Latin America is projected to reach USD 0.32 billion in 2026, while the GCC market is expected to reach USD 0.15 billion. South Africa is estimated at approximately USD 0.05 billion in 2026.
COMPETITIVE LANDSCAPE
Key companies operating in the market include Thermo Fisher Scientific Inc., SGS Societe Generale de Surveillance SA, Labcorp, IQVIA, Charles River Laboratories, Eurofins Scientific, Intertek Group plc, Wuxi AppTec, Pharmaron, and Frontage Labs. Companies are focusing on laboratory expansion, certifications, advanced analytical capabilities, acquisitions, and expanded service portfolios.
Recent industry developments include SGS acquisitions of CMIC and Keystone Bioanalytical in 2026, BioAgilytix investment in LC/MS capabilities in October 2025, Synexa Life Sciences' acquisition of Alderley Analytical in October 2024, and IQVIA's expansion of its central laboratory and biorepository operations in Valencia, California, in October 2024.
REPORT COVERAGE
The report provides a detailed analysis of the global bioanalytical testing services market, including market size and forecast, major growth drivers, restraints, opportunities, challenges, trends, segmentation by analytical testing type, molecule, technology, and end user, regional analysis, competitive landscape, key companies, and recent industry developments. The market is valued at USD 5.72 billion in 2025, projected at USD 6.26 billion in 2026, and expected to reach USD 12.30 billion by 2034.
CONCLUSION
The global bioanalytical testing services market is expected to expand steadily from USD 5.72 billion in 2025 to USD 6.26 billion in 2026 and USD 12.30 billion by 2034, at a CAGR of 8.8%. Growth will be supported by expanding pharmaceutical and biotechnology R&D pipelines, increasing development of biologics and advanced therapies, greater outsourcing of analytical activities, adoption of automation and digital laboratory technologies, and growing clinical research activity. North America is expected to remain an important market, while Europe and Asia Pacific will continue developing through pharmaceutical investment, laboratory expansion, and increasing healthcare and clinical research activity.
Segmentation By Analytical Testing Type, Molecule, Technology, End User, and Region
By Analytical Testing Type
- Pharmacokinetic/Toxicokinetic and Drug Concentration Analysis
- Immunogenicity Testing
- Biomarker and Pharmacodynamic Analysis
- Metabolite Profiling and Identification
- Others
By Molecule
- Small Molecules
- Large Molecules & Conventional Biologics
- Advanced Therapeutic Modalities
By Technology
- Direct Chromatography-Mass Spectrometry
- Ligand-Binding & Immunoassays
- Flow Cytometry
- Others
By End User
- Pharmaceutical & Biotechnology Companies
- CROs & CDMOs
- Academic & Research Institutes
- Others
By Region
- North America (By Analytical Testing Type, By Molecule, By Technology, By End User, and by Country)
- U.S. (By Molecule)
- Canada (By Molecule)
- Europe (By Analytical Testing Type, By Molecule, By Technology, By End User, and by Country/Sub-region)
- U.K. (By Molecule)
- Germany (By Molecule)
- France (By Molecule)
- Italy (By Molecule)
- Spain (By Molecule)
- Scandinavia (By Molecule)
- Rest of Europe (By Molecule)
- Asia Pacific (By Analytical Testing Type, By Molecule, By Technology, By End User, and by Country/Sub-region)
- China (By Molecule)
- Japan (By Molecule)
- India (By Molecule)
- Australia (By Molecule)
- Southeast Asia (By Molecule)
- Rest of Asia Pacific (By Molecule)
- Latin America (By Analytical Testing Type, By Molecule, By Technology, By End User, and by Country/Sub-region)
- Brazil (By Molecule)
- Mexico (By Molecule)
- Rest of Latin America (By Molecule)
- Middle East & Africa (By Analytical Testing Type, By Molecule, By Technology, By End User, and by Country/Sub-region)
- GCC (By Molecule)
- South Africa (By Molecule)
- Rest of Middle East & Africa (By Molecule)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Challenges
- 3.5. Market Trends
4. Key Insights
- 4.1. Overview of Healthcare Expenditure, Key Countries/Regions, 2025
- 4.2. Number of Clinical Studies, Key Countries/Region, 2025
- 4.3. Key Industry Developments - Mergers, Acquisitions & Partnerships
5. Global Bioanalytical Testing Services Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Analytical Testing Type
- 5.1.1. Pharmacokinetic/Toxicokinetic and Drug Concentration Analysis
- 5.1.2. Immunogenicity Testing
- 5.1.3. Biomarker and Pharmacodynamic Analysis
- 5.1.4. Metabolite Profiling and Identification
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast - By Molecule
- 5.2.1. Small Molecules
- 5.2.2. Large Molecules & Conventional Biologics
- 5.2.3. Advanced Therapeutic Modalities
- 5.3. Market Analysis, Insights and Forecast - By Technology
- 5.3.1. Direct Chromatography-Mass Spectrometry
- 5.3.2. Ligand-Binding & Immunoassays
- 5.3.3. Flow Cytometry
- 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast - By End User
- 5.4.1. Pharmaceutical & Biotechnology Companies
- 5.4.2. CROs & CDMOs
- 5.4.3. Academic & Research Institutes
- 5.4.4. Others
- 5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Bioanalytical Testing Services Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Analytical Testing Type
- 6.1.1. Pharmacokinetic/Toxicokinetic and Drug Concentration Analysis
- 6.1.2. Immunogenicity Testing
- 6.1.3. Biomarker and Pharmacodynamic Analysis
- 6.1.4. Metabolite Profiling and Identification
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast - By Molecule
- 6.2.1. Small Molecules
- 6.2.2. Large Molecules & Conventional Biologics
- 6.2.3. Advanced Therapeutic Modalities
- 6.3. Market Analysis, Insights and Forecast - By Technology
- 6.3.1. Direct Chromatography-Mass Spectrometry
- 6.3.2. Ligand-Binding & Immunoassays
- 6.3.3. Flow Cytometry
- 6.3.4. Others
- 6.4. Market Analysis, Insights and Forecast - By End User
- 6.4.1. Pharmaceutical & Biotechnology Companies
- 6.4.2. CROs & CDMOs
- 6.4.3. Academic & Research Institutes
- 6.4.4. Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.1.1. By Molecule
- 6.5.2. Canada
- 6.5.2.1. By Molecule
- 6.5.1. U.S.
7. Europe Bioanalytical Testing Services Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Analytical Testing Type
- 7.1.1. Pharmacokinetic/Toxicokinetic and Drug Concentration Analysis
- 7.1.2. Immunogenicity Testing
- 7.1.3. Biomarker and Pharmacodynamic Analysis
- 7.1.4. Metabolite Profiling and Identification
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast - By Molecule
- 7.2.1. Small Molecules
- 7.2.2. Large Molecules & Conventional Biologics
- 7.2.3. Advanced Therapeutic Modalities
- 7.3. Market Analysis, Insights and Forecast - By Technology
- 7.3.1. Direct Chromatography-Mass Spectrometry
- 7.3.2. Ligand-Binding & Immunoassays
- 7.3.3. Flow Cytometry
- 7.3.4. Others
- 7.4. Market Analysis, Insights and Forecast - By End User
- 7.4.1. Pharmaceutical & Biotechnology Companies
- 7.4.2. CROs & CDMOs
- 7.4.3. Academic & Research Institutes
- 7.4.4. Others
- 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.5.1. U.K.
- 7.5.1.1. By Molecule
- 7.5.2. Germany
- 7.5.2.1. By Molecule
- 7.5.3. France
- 7.5.3.1. By Molecule
- 7.5.4. Spain
- 7.5.4.1. By Molecule
- 7.5.5. Italy
- 7.5.5.1. By Molecule
- 7.5.6. Scandinavia
- 7.5.6.1. By Molecule
- 7.5.7. Rest of Europe
- 7.5.7.1. By Molecule
- 7.5.1. U.K.
8. Asia Pacific Bioanalytical Testing Services Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Analytical Testing Type
- 8.1.1. Pharmacokinetic/Toxicokinetic and Drug Concentration Analysis
- 8.1.2. Immunogenicity Testing
- 8.1.3. Biomarker and Pharmacodynamic Analysis
- 8.1.4. Metabolite Profiling and Identification
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast - By Molecule
- 8.2.1. Small Molecules
- 8.2.2. Large Molecules & Conventional Biologics
- 8.2.3. Advanced Therapeutic Modalities
- 8.3. Market Analysis, Insights and Forecast - By Technology
- 8.3.1. Direct Chromatography-Mass Spectrometry
- 8.3.2. Ligand-Binding & Immunoassays
- 8.3.3. Flow Cytometry
- 8.3.4. Others
- 8.4. Market Analysis, Insights and Forecast - By End User
- 8.4.1. Pharmaceutical & Biotechnology Companies
- 8.4.2. CROs & CDMOs
- 8.4.3. Academic & Research Institutes
- 8.4.4. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.5.1. Japan
- 8.5.1.1. By Molecule
- 8.5.2. Australia
- 8.5.2.1. By Molecule
- 8.5.3. China
- 8.5.3.1. By Molecule
- 8.5.4. India
- 8.5.4.1. By Molecule
- 8.5.5. Southeast Asia
- 8.5.5.1. By Molecule
- 8.5.6. Rest of Asia Pacific
- 8.5.6.1. By Molecule
- 8.5.1. Japan
9. Latin America Bioanalytical Testing Services Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Analytical Testing Type
- 9.1.1. Pharmacokinetic/Toxicokinetic and Drug Concentration Analysis
- 9.1.2. Immunogenicity Testing
- 9.1.3. Biomarker and Pharmacodynamic Analysis
- 9.1.4. Metabolite Profiling and Identification
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast - By Molecule
- 9.2.1. Small Molecules
- 9.2.2. Large Molecules & Conventional Biologics
- 9.2.3. Advanced Therapeutic Modalities
- 9.3. Market Analysis, Insights and Forecast - By Technology
- 9.3.1. Direct Chromatography-Mass Spectrometry
- 9.3.2. Ligand-Binding & Immunoassays
- 9.3.3. Flow Cytometry
- 9.3.4. Others
- 9.4. Market Analysis, Insights and Forecast - By End User
- 9.4.1. Pharmaceutical & Biotechnology Companies
- 9.4.2. CROs & CDMOs
- 9.4.3. Academic & Research Institutes
- 9.4.4. Others
- 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.5.1. Brazil
- 9.5.1.1. By Molecule
- 9.5.2. Mexico
- 9.5.2.1. By Molecule
- 9.5.3. Rest of Latin America
- 9.5.3.1. By Molecule
- 9.5.1. Brazil
10. Middle East & Africa Bioanalytical Testing Services Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Analytical Testing Type
- 10.1.1. Pharmacokinetic/Toxicokinetic and Drug Concentration Analysis
- 10.1.2. Immunogenicity Testing
- 10.1.3. Biomarker and Pharmacodynamic Analysis
- 10.1.4. Metabolite Profiling and Identification
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast - By Molecule
- 10.2.1. Small Molecules
- 10.2.2. Large Molecules & Conventional Biologics
- 10.2.3. Advanced Therapeutic Modalities
- 10.3. Market Analysis, Insights and Forecast - By Technology
- 10.3.1. Direct Chromatography-Mass Spectrometry
- 10.3.2. Ligand-Binding & Immunoassays
- 10.3.3. Flow Cytometry
- 10.3.4. Others
- 10.4. Market Analysis, Insights and Forecast - By End User
- 10.4.1. Pharmaceutical & Biotechnology Companies
- 10.4.2. CROs & CDMOs
- 10.4.3. Academic & Research Institutes
- 10.4.4. Others
- 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.5.1. GCC
- 10.5.1.1. By Molecule
- 10.5.2. South Africa
- 10.5.2.1. By Molecule
- 10.5.3. Rest of Middle East & Africa
- 10.5.3.1. By Molecule
- 10.5.1. GCC
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Thermo Fisher Scientific Inc.
- 11.2.2. SGS Societe Generale de Surveillance SA
- 11.2.3. Labcorp
- 11.2.4. IQVIA
- 11.2.5. Charles River Laboratories
- 11.2.6. Eurofins Scientific
- 11.2.7. Intertek Group plc
- 11.2.8. Wuxi AppTec
- 11.2.9. Pharmaron
- 11.2.10. Frontage Labs
